Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Mar
03
Today In Oncology
Fifteen-Year Results From SWOG S0016 Suggest Follicular Lymphoma May Be Curable
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer
AI Model May Predict Cancer Risk in Patients With Colitis-Associated Low-Grade Dysplasia
Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
Advanced RCC After Immunotherapy Belzutifan Plus Lenvatinib or Cabozantinib
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo